drugset / Trial / NCT02596243

Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)

NCT02596243

Phase 2 Unknown 134 enrolled Genexine, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to access the efficacy and safety of GX-188E according the protocol in patients with Cervical Intraepithelial Neoplasia 2, 2/3 or 3 (CIN3)

Timeline

Start
2015-08
Primary completion
2018-03
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject GX-188E Vaccine 1 mg Intramuscular